NPR ran an updated story on the ‘battle’ between compounders and drug makers over GLP-1 weight-loss...
Endpoints shares our FDA letter
Adding to the list of larger news outlets covering what APC is up to is Endpoints News (from the Financial Times). It wrote about our letter to the FDA that pointed out that semaglutide isn’t difficult to compound, despite erroneous claims by Novo Nordisk.